What is the dosage of Cyramza?

Cyramza is available in 2 dosages, including 10 mg/ml Injection 50 ml and 10 mg/ml Injection 10 ml

What is Cyramza mechanism of action?

Cyramza mechanism of action is VEGFR2 Inhibitors

Cyramza Prescribing & Dosing Schedule

Q: What does Cyramza treat?

Cyramza treats Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms and Colorectal Neoplasms

Q: What is Cyramza made of?

Cyramza contains ramucirumab which is a Vascular Endothelial Growth Factor Receptor 2 Antagonist

Q: How is Cyramza administered?

Cyramza is administered as a Injectable

Dosage & Administration

* For intravenous infusion only. Do not administer as an intravenous push or bolus.
* Premedicate before each infusion.
* Gastric Cancer: Administer CYRAMZA 8 mg/kg every 2 weeks as a single agent or in combination with weekly paclitaxel.
* Non-Small Cell Lung Cancer:
* Administer CYRAMZA 10 mg/kg every 2 weeks with daily erlotinib.
* Administer CYRAMZA 10 mg/kg on Day 1 of a 21-day cycle prior to docetaxel.

* Colorectal Cancer: Administer CYRAMZA 8 mg/kg every 2 weeks prior to FOLFIRI.
* Hepatocellular Carcinoma: Administer CYRAMZA 8 mg/kg every 2 weeks.

Get Your Patient on Cyramza

See your patient's specific prior authorization requirements including coverage restrictions and step therapies

Or select your Insurance from the list below:

Cyramza Prescribing Information

Contact Medical Science Liaison

Report Adverse Event

Cyramza Prior Authorization Resources

Most recent state uniform prior authorization forms

Verified: Sep 24, 2024Arizona - Uniform Prior Authorization Form

Verified: Sep 24, 2024Colorado - Uniform Prior Authorization Form

Verified: Sep 24, 2024Hawaii - Uniform Prior Authorization Form

Verified: Sep 24, 2024Illinois - Uniform Prior Authorization Form

Verified: Sep 24, 2024Indiana - Uniform Prior Authorization Form

Verified: Sep 24, 2024Louisiana - Uniform Prior Authorization Form

Verified: Sep 24, 2024Minnesota - Uniform Prior Authorization Form

Verified: Sep 24, 2024New Hampshire - Uniform Prior Authorization Form

Verified: Sep 24, 2024New Mexico - Uniform Prior Authorization Form

Verified: Sep 24, 2024Oregon - Uniform Prior Authorization Form

Verified: Sep 24, 2024Texas - Uniform Prior Authorization Form

Verified: Oct 05, 2024Washington - Uniform Prior Authorization Form

Verified: Oct 05, 2024Wisconsin - Uniform Prior Authorization Form

Coverage Authorization Appeals

Coverage Authorization Appeals: Second Level

Denied Claims Checklist

First-Level Medicare Review Letter

Complete Letter of Medical Necessity

Second-Level Medicare Review Letter

Benefits investigation

Lilly Oncology Support Center - Infused Products Enrollment Form

Reimbursement help (FRM)

Receive Assistance from an FRM Regarding Reimbursement Information

Cyramza Preferred Pharmacy

Pharmacy List

Cyramza Financial Assistance Options

Copay savings program

Lilly Oncology Support Center - Infused Products Enrollment Form

Enroll in Patient Savings Program

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Foundation programs

Lilly Cares Foundation Eligibility Check

Learn More

Overview

Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned

Patient benefit

Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and copays) until the grant is exhausted

Patient eligibility

Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.